Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: georgiabiotech who wrote (23779)	5/23/2007 9:19:24 PM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 52153

The comments in 23734 were from another poster on IH. It is pretty clear that he was off the mark in his use of cross-study data. My comments made earlier still appear to be valid: Message 23561195 As others have pointed out, my arguments fail to appreciate the hazard ratio differences. While that is true, it still seems to me that data selected after the fact and compiled from multiple studies should face a higher than normal P-value hurdle before we bow at the Nissan alter. :-) This odyssey in stat-land has finally convinced me WHY I would never want to be a statistician. ij